Design and Development of Gold-Loaded and Boron-Attached Multicore Manganese Ferrite Nanoparticles as a Potential Agent in Biomedical Applications

ACS Omega. 2022 Jun 3;7(23):20195-20203. doi: 10.1021/acsomega.2c02074. eCollection 2022 Jun 14.

ABSTRACT

Early diagnosis and effective treatment of cancer are significant issues that should be focused on since it is one of the most deadly diseases. Multifunctional nanomaterials can offer new cancer diagnoses and treatment possibilities. These nanomaterials with diverse functions, including targeting, imaging, and therapy, are being studied extensively in a way that minimize overcoming the limitations associated with traditional cancer diagnosis and treatment. Therefore, the goal of this study is to prepare multifunctional nanocomposites possessing the potential to be used simultaneously in imaging such as magnetic resonance imaging (MRI) and dual cancer therapy such as photothermal therapy (PTT) and boron neutron capture therapy (BNCT). In this context, multi-core MnFe2O4 nanoparticles, which can be used as a potential MRI contrast agent and target the desired region in the body via a magnetic field, were successfully synthesized via the solvothermal method. Then, multi-core nanoparticles were coated with polydopamine (PDA) to reduce gold nanoparticles, bind boron on the surface, and ensure the biocompatibility of all materials. Finally, gold nanoparticles were reduced on the surface of PDA-coated MnFe2O4, and boric acid was attached to the hybrid materials for also possessing the ability to be used as a potential agent in PTT and BNCT applications in addition to being an MRI agent. According to the cell viability assay, treatment of the glioblastoma cell line (T98G) with MnFe2O4@PDA-Au-BA for 24 and 48 h did not cause any significant cell death, indicating good biocompatibility. All analysis results showed that the developed MnFe2O4@PDA-Au-BA multifunctional material could be a helpful candidate for biomedical applications such as MRI, PTT, and BNCT.

PMID:35721900 | PMC:PMC9201883 | DOI:10.1021/acsomega.2c02074

Share:

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *